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Abstract
Background: HIV-infected patients could exhibit accelerated ageing, since age-associated complications like
sarcopenia; increased inflammation; lipodystrophy with loss of subcutaneous adipose tissue and/or gain of visceral
adipose tissue (VAT); and cardiovascular disease occur at an earlier age. Inflammation is involved in age-associated
complications. However, it is not understood whether it is the same inflammatory changes that are involved in the
various ageing-associated complications. Our objective was to study whether leptin, interleukin 6 (IL-6), and soluble
urokinase plasminogen activator receptor (suPAR) were associated distinctively with adiposity, lipodystrophy and
sarcopenia, in HIV-infected patients and healthy Controls.
Results: Systemic leptin levels were significantly higher in patients with lipodystrophy than without, whereas there
was no difference in IL-6 or suPAR levels. Leptin was significantly positively associated with fat mass index (FMI) and
abdominal VAT, but not with lean mass index (LMI). IL-6 was significantly associated with both FMI and VAT, and
low LMI. High suPAR was associated with low LMI, and weakly with high FMI and VAT.
Conclusions: Leptin reflected adiposity- and lipodystrophy-related inflammation, but not sarcopenia. IL-6 reflected
both adiposity-, but also sarcopenia-related inflammation; and suPAR was a marker of sarcopenia-related inflammation.
Our results indicate that different inflammatory processes can be active simultaneously contributing to the systemic
low grade inflammatory state. Identifying major contributors to circulating leptin, IL-6, and suPAR levels could levels
could therefore improve our understanding of which inflammatory processes are involved in the various age-related
complications.
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Background
Inflammation could be a driver of biological ageing,
since inflammation increases with age; is elevated in
ageing-associated conditions like sarcopenia, and dys-
metabolism; and is a risk factor for cardiovascular
disease, type 2 diabetes, cancer, and overall mortality
[1–6]. Accordingly, HIV-infected patients could ex-
hibit accelerated ageing, as combination antiretroviral
therapy (cART)-treated HIV-infected patients exhibit
higher inflammatory levels and develop cardiovascular
disease, type 2 diabetes, and maybe sarcopenia at a
younger age than population controls [7–11]. More-
over, 30–60 % of HIV-infected patients exhibit altered
adipose tissue (AT) distribution termed lipodystrophy.
Lipodystrophy is characterised by loss of SAT (lipoatrophy)
and/or gain of visceral adipose tissue (VAT) (lipohy-
pertrophy), resembling an extreme form of age-
associated AT redistribution. Lipodystrophy is caused
by a combination of the infection and cART [12–16], and
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is associated with insulin resistance, systemic and adipose
tissue inflammation [17, 18].
It is well-established that inflammation is elevated in
the majority of age-associated complications. However, it
is still not understood whether this is a general inflam-
matory mechanism, or whether the inflammatory bio-
markers reflect different co-existing pathophysiological
processes. A major limitation for understanding this, has
been inconsistent adjustment for confounders with major
impact on inflammation, such as not assessing muscle
mass when assessing fat mass. Our aim was therefore to
study whether leptin, interleukin 6 (IL-6), and soluble uro-
kinase plasminogen activator receptor (suPAR) were asso-
ciated distinctively with adiposity, lipodystrophy and
sarcopenia, in HIV-infected patients and healthy Controls.
Leptin is a central adipokine produced in levels propor-
tional to fat cell mass [19, 20]. Leptin integrates inflamma-
tion, metabolism and neuroendocrine signalling thereby
regulating energy consumption and storage. Obesity is as-
sociated with increased leptin levels, and leptin resistance
may be a characteristic of obesity contributing to insulin
resistance and lipotoxicity [20]. Leptin levels are altered in
lipodystrophy, and leptin therapy has been applied to im-
prove insulin sensitivity in HIV-associated lipoatrophy,
but with diverging results [21–23]. It is not established
whether leptin levels are altered in lipodystrophy merely
as a result of the AT mass, or whether AT redistribution
affects leptin levels.
IL-6 is a pleiotropic cytokine produced by numerous cell
types such as adipocytes, myocytes, and leukocytes. In-
creased IL-6 levels are associated with obesity, muscle ca-
tabolism, cardiovascular disease, and mortality [1, 24–26].
Paradoxically, IL-6 is also produced by skeletal muscle
during exercise where it mediates beneficial effects of ex-
ercise, independently of muscle damage [25]. IL-6 is ele-
vated in HIV, but IL-6 levels appear not to be affected in
lipodystrophy [8, 18]. How IL-6 reflects and affects AT
and muscle mass in HIV-infection and lipodystrophy is
not clear.
suPAR is produced when uPAR is cleaved from the cell
surface, primarily from activated T cells, monocytes,
neutrophils and endothelial cells. suPAR correlates with
other inflammatory proteins such as TNF-α, and suPAR
levels are elevated in a variety of diseases like HIV, sep-
sis, cardiovascular disease, and cancer. The function of
suPAR is not well-established, but patients with the
highest suPAR levels generally have the worst prognosis
[2, 27, 28]. In contrast to many other inflammatory
markers, suPAR associates weakly with AT measures, but
strongly with low lean mass [2, 29, 30]. suPAR could
therefore reflect a distinct type of inflammation related to
sarcopenia but not AT.
We found that leptin reflected adiposity- and lipo-
dystrophy-related inflammation, but not sarcopenia. IL-6
reflected both adiposity-, but also sarcopenia-related in-
flammation; and suPAR was a marker of sarcopenia-
related inflammation. Our results indicate that different
inflammatory processes can be active simultaneously con-
tributing to the systemic low grade inflammatory state.
Results
We included 60 HIV-infected patients, 24 with lipody-
strophy (Lipo), 36 without lipodystrophy (Non-Lipo),
and 16 healthy Controls. One Control was excluded
from data analyses due to recent hip-surgery, see Fig. 1.
Eight patients did not have DXA scans made. Two pa-
tients did not have CT scans made.
Adipose tissue distribution and metabolic parameters in
lipodystrophy subgroups
The Lipo group comprised: 10 patients with lipoatrophy
(Atrophy), 4 patients with lipohypertrophy (Hyper), and 10
patients with both lipoatrophy and lipohypertrophy (Mix),
see Fig. 1. Mean SAT was 101 cm2 for Atrophy, 300 cm2
Fig. 1 Overview of Cohort. Of the 24 HIV-infected patients with lipodystrophy, 10 had lipoatrophy (Atrophy), 4 had lipohypertrophy (Hyper), and
10 had Mixed type lipodystrophy (Mix). Patients with Hyper and Mix type lipodystrophy were grouped (Hyper/Mix). One control was excluded
from data analyses due to recent hip surgery. Two patients with Atrophy, 1 Mix, and five patients without lipodystrophy (Non-Lipo) did not have
DXA made, and were therefore not included in analyses of DXA scans. Two patients in the Non-Lipo did not have CT made, and were therefore
not included in analyses of CT scans. Abbreviations: CT: Computed tomography; DXA: Dual energy X-ray absorptiometry
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for Hyper, and 221 cm2 for Mix. Mean VAT was 128 cm2
for Atrophy, 285 cm2 for Hyper, and 222 cm2 for Mix. The
mean VAT/SAT ratio was 1.5 for Atrophy, 1.0 for Hyper,
and 1.2 for Mix. Mean homeostatic model assessment of
insulin resistance (HOMA-IR) was 0.9 for Atrophy; 2.1 for
Hyper; and 4.9 for Mix. Metabolic syndrome was present in
10 % in Atrophy; 75 % in Hyper; and 90 % in Mix. Since
lipoatrophy and lipohypertrophy could be caused by dis-
tinct disease processes, we decided to analyse Lipo in sub-
groups. Hyper and Mix (Hyper/Mix) were grouped for
further analyses, due to the low number of patients with
lipohypertrophy, and the fact that Hyper and Mix had simi-
lar VATand metabolic risk factors compared to Atrophy.
Baseline characteristics of atrophy, hyper/mix, non-lipo
and controls
Baseline characteristics for Atrophy, Hyper/Mix, Non-
Lipo and Controls are shown in Table 1. Patients in the
Hyper/Mix group were significantly older than Non-
Lipo. Both Atrophy and Hyper/Mix had significantly
longer HIV and treatment duration, and a higher percent
of patients previously treated with thymidine nucleoside
reverse transcriptase inhibitors (tNRTI) than the Non-
Lipo group. Smoking was significantly more prevalent,
and triglyceride and very low density lipoprotein (VLDL)
levels were significantly higher in Non-Lipo compared to
Controls. BMI, FMI, SAT and tLMI was significantly
Table 1 Baseline Characteristics
Variable Atrophy (N = 10) Hyper/Mix (N = 4 + 10) Non-Lipo (N = 36) Controls (N = 15)
Demography and lifestyle
Age (years) 50.1 (46.2; 47.5) 58.1 (54.0; 64.1)* 48.3 (40.1; 53.9) 47.6 (40.9; 62.3)
Smoking (N (%)) 4 (40.0 %) 2 (14.3 %) 12 (33.3 %) 1 (6.7 %)*
Body composition
BMI (kg/m2) 21.1 (19.4; 24.1)* 27.2 (24.7; 29.3) 25.5 (23.2; 28.2) 25.4 (22.2; 29.7)
FMI (kg/m2) 2.4 (1.6; 3.2)* 5.4 (4.0; 7.1) 4.8 (3.6; 6.7) 4.8 (4.4; 7.5)
VAT (cm2) 136.7 (91.7; 160.4) 251.0 (178.9; 280.9)* 136.4 (96.8; 194.3) 120.2 (93.5; 159.8)
SAT (cm2) 105.5 (56.4; 129.1)* 254.8 (203.2; 294.6) 197.4 (152.1; 264.1) 253.5 (146.2; 310.9)
VAT/SAT 1.4 (1.1; 1.8)* 0.8 (0.7; 1.6)* 0.7 (0.5; 0.9) 0.5 (0.4; 0.8)
tLMI (kg/m2) 17.1 (15.7; 18.4)* 20.3 (18.4; 20.6) 18.4 (17.1; 20.6) 18.4 (18.0; 20.6)
lLMI (kg/m2) 5.5 (5.0; 6.6) 6.3 (6.0; 6.7) 6.1 (5.7; 6.7) 6.5 (6.2; 7.0)
Metabolism
Triglyceride 1.3 (1.1; 2.1) 1.4 (1.2; 2.4) 1.6 (1.0; 2.0) 0.9 (0.7; 1.1)*
Cholesterol 5.3 (4.6;6.4) 5.5 (4.8; 6.6) 5.4 (4.8; 6.4) 5.4 (4.7; 5.7)
HDL 1.4 (1.2; 1.5) 1.3 (1.0; 1.5) 1.3 (1.1; 1.5) 1.4 (1.3; 1.6)
VLDL 0.6 (0.5; 0.9) 0.5 (0.5; 0.9) 0.7 (0.5; 0.9) 0.4 (0.3; 0.5)*
LDL 3.2 (2.5; 4.2) 3.2 (2.7; 3.8) 3.4 (3.0; 4.5) 3.1 (2.6; 3.8)
HOMA-IR 0.9 (0.5; 1.2) 2.4 (1.6; 4.1)* 0.9 (0.5; 2.1) 0.5 (0.5; 1.3)*
Metabolic syndrome, N(%) 1 (10.0 %) 12 (85.7 %)* 14 (38.9 %) 2 (13.3 %)
HIV
HIV duration (years) 19.5 (17.8; 25.6)* 20.8 (16.5; 24.4)* 11.0 (4.9; 16.2) -
cART duration (years) 15.3 (12.6; 18.4)* 15.2 (13.6; 16.3)* 5.8 (3.5; 13.0) -
Current tNRTI 0 (0 %) 0 (0 %) 1 (2.8 %) -
Previous tNRTI 9 (100.0 %)*a 14 (100.0 %)* 18 (53.0 %)a -
HIV RNA≤ 20 copies/mL 9 (90.0 %) 14 (100.0 %) 32 (88.9 %) -
CD4+ T cells/μL 716 (569; 830) 593 (534; 910) 535 (393; 736) 739 (598; 880)*
CD8+ T cells/μL 1090 (802; 1160) 654 (583; 829) 821 (597; 1160) 397 (281; 493)*
CD4+:CD8+ ratio 0.7 (0.6; 0.8) 1.0 (0.7;1.3) 0.7 (0.5; 0.9) 1.9 (1.5; 3.0)*
The table depicts median (25; 75 percentiles). *:p < 0.05 between groups and Non-Lipo. aPrevious treatment data missing from one patient in Atrophy and two
patients in the Non-Lipo group
Abbreviations: BMI body mass index, cART combination antiretroviral treatment, FMI fat mass index, HDL high density lipoprotein, HOMA-IR homeostatic model
assessment of insulin resistance, IL-6 Interleukin 6, LDL low density lipoprotein, suPAR soluble urokinase plasminogen activator receptor, SAT subcutaneous adipose
tissue, tNRTI thymidine nucleoside reverse transcriptase inhibitors, VAT Visceral adipose tissue, VLDL very low density lipoprotein
We analysed differences between groups and Non-Lipo. Data were analysed using one-way Anova. BMI, FMI, HDL, SAT, triglycerides, VAT/SAT, VLDL, HOMA, and
CD4 was analysed using Kruskal-Wallis test. Smoking, metabolic syndrome, previous tNRTI, and HIV RNA ≤ 20 copies/mL were analysed using Fisher’s exact test
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lower in Atrophy compared to Non-Lipo, whereas there
was no significant difference between Hyper/Mix and
Non-Lipo, and Non-Lipo and Controls. In contrast, VAT
was significantly higher in Hyper/Mix compared to
Non-Lipo, and both Atrophy and Hyper/Mix had signifi-
cantly higher VAT/SAT ratio than Non-Lipo. HOMA-IR
was significantly higher and metabolic syndrome signifi-
cantly more prevalent in Hyper/Mix than Non-Lipo,
whereas there was no difference between Atrophy and
Non-Lipo.
Associations between leptin, IL-6, and suPAR with age,
smoking, lipodystrophy, and HIV
In univariate regression analyses, neither leptin nor IL-6
were associated with higher age, but suPAR tended to be
(p = 0.05). IL-6 (p = 0.004) and suPAR (p < 0.001) were
significantly higher in daily smokers than non-daily
smokers, whereas leptin levels tended to be lower in
daily smokers (39.5 % lower, p = 0.06). In univariate re-
gression analyses, leptin levels were significantly lower in
Atrophy than Non-Lipo (60 % lower, p = 0.007), and
significantly higher in Hyper/Mix than Non-Lipo
(105 % higher, p = 0.02), see Fig. 2 and Table 2. In
contrast, there was no significant difference in IL-6
or suPAR levels between Lipo subgroups and Non-
Lipo. Leptin levels were not significantly different in
Non-Lipo and Controls, whereas IL-6 and suPAR
were significantly higher in Non-Lipo compared to
Controls (IL-6: p = 0.03; suPAR: p = 0.02), see Fig. 2
and Table 2. Furthermore, we found no associations
between the biomarkers and previous treatment with
tNRTI or duration of the infection or cART (data
not shown).
Univariate associations between leptin, IL-6, and suPAR
with body composition
Leptin and IL-6 were strongly associated with high FMI
and VAT, whereas suPAR was not (Table 2). Leptin was
significantly correlated with high tLMI and lLMI;
whereas suPAR was significantly correlated with low
tLMI and lLMI (Table 2). IL-6 was not significantly cor-
related with either tLMI or lLMI.
Interaction analyses for the univariate association between
biomarkers and body composition in the four groups
The association between leptin and body composition
was significantly modified by group, whereas the asso-
ciation of IL-6 and suPAR with body composition was
not, see Fig. 3. The association between leptin and
FMI was stronger for Controls (p < 0.001) and Atro-
phy (p = 0.05) than for Non-Lipo, though only signifi-
cantly different for Controls. Moreover, we found a
tendency of leptin to be more strongly associated with
VAT for Controls (p = 0.06) than for Non-Lipo. The posi-
tive association between leptin and lLMI was abrogated in
the Hyper/Mix group (p = 0.01), see Fig. 3.
Relation between fat and muscle mass
We investigated whether fat and muscle were associated, as
found in previous studies. High FMI was significantly asso-
ciated with high tLMI (p < 0.001) and lLMI (p < 0.001), see
Fig. 4 left. We tested whether the association between fat
and muscle mass was modified by group. In the Hyper/
Mix group, FMI appeared not to be associated with
lLMI (p = 0.08 versus Non-Lipo) or tLMI (p = 0.08
versus Non-Lipo). However, when removing an influ-
ential outlier from the Hyper/Mix group, the association
between FMI and lLMI or tLMI was not significantly differ-
ent in Hyper/Mix and Non-Lipo (p = 0.42; tLMI: p = 0.40
versus Non-Lipo), as seen in Fig. 4 right.
Adjusted analyses for leptin, IL-6, and suPAR and the
associations with age, smoking, lipodystrophy, and HIV
Adjusted for group, none of the biomarkers were signifi-
cantly associated with age. IL-6 and suPAR were signifi-
cantly elevated in daily smokers, when adjusting for age
Fig. 2 Leptin, IL-6 and suPAR levels in Atrophy, Hyper/Mix, Non-Lipo and Controls. Individuals are depicted by circles, black circles indicate individuals
with lipohypertrophy. Median is presented with a line. *p < 0.05 between groups, using general linear regression
Langkilde et al. Immunity & Ageing  (2015) 12:9 Page 4 of 11
and group. We performed multiple regression analyses
for the association between biomarkers, body compos-
ition and lipodystrophy, adjusted for both FMI and lLMI
to account for the interrelation between fat and muscle
mass. Results are shown in Table 2. Adjusted for age,
smoking, FMI and lLMI we found 128.3 % higher leptin
levels in Hyper/Mix compared to Non-Lipo (p < 0.001),
but no difference between Atrophy or Controls and
Non-Lipo. IL-6 and suPAR levels were not altered in
Hyper/Mix or Atrophy compared to Non-Lipo, but IL-6
Fig. 3 Leptin levels and Body Composition, stratified by group. The figure shows individuals from each group and group-specific regression lines
and the equations for the regression lines. If the association is significantly different from Non-Lipo, the legend is marked with a*. Atrophy is
presented by red circles and the regression line is thick, solid and red; Hyper/Mix by green and squares, and the regression line is thin, solid and
green; Controls by black and triangles, and the regression line is thick, dotted and black. Non-Lipo by blue and plus, and the regression line is
thin, dotted, and blue. Abbreviation: VAT: visceral adipose tissue
Table 2 Univariate and multiple regression analyses
Univariate % Estimate (p) Multiple % Estimate (p)
Leptin IL-6 suPAR Leptin IL-6 suPAR
Age (years) 0.9 (0.45) 0.5 (0.53) 0.6 (0.05) 0.01 (1.0) 0.4 (0.64) 0.5 (0.10)
Daily smoking −39.5 (0.06) 65.8 (0.004) 33.6 (<0.001) −32.8 (0.13) 63.6 (0.007) 36.7 (<0.001)
Atrophy vs. Non-Lipo −60.0 (0.007) −17.8 (0.41) −11.2 (0.24) −5.1 (0.82) 6.2 (0.81) −5.1 (0.57)
Hyper/Mix vs. Non-Lipo 104.5 (0.02) −0.1 (0.99) 6.6 (0.47) 128.3 (<0.001) 3.3 (0.87) 3.4 (0.63)
Non-Lipo vs. Controls 16.4 (0.59) 58.3 (0.03) 23.2 (0.02) 1.6 (0.93) 27.4 (0.21) 9.9 (0.17)
FMI (kg/m2) 35.3 (<0.001) 8.0 (0.009) 0.1 (0.95) 33.5 (<0.001) 15.1 (<0.001) 3.5 (0.006)
VAT (cm2) 0.9 (<0.001) 0.3 (0.001) 0.1 (0.19) 0.8 (<0.001) 0.5 (<0.001) 0.1 (0.009)
tLMI (kg/m2) 26.4 (<0.001) −1.3 (0.70) −3.0 (0.03) 0.2 (0.95) −10.8 (0.003) −5.5 (0.002)
lLMI (kg/m2) 76.6 (<0.001) −4.9 (0.61) −10.6 (0.003) −0.6 (0.95) −20.7 (0.03) −12.7 (<0.001)
Biomarker levels were transformed using log2(x) in univariate and multiple analyses. Results are therefore back-transformed using (1-2
β)*100 and shown as percent
estimates per unit increase. Associations where p <0.05 are bold
Abbreviations: BMI body mass index, FMI fat mass index, tLMI total lean mass index, lLMI leg lean mass index, VAT visceral adipose tissue
Multiple analyses adjustments: Age was adjusted for group. Daily smoking was adjusted for age and group. Group analyses were adjusted for age, smoking, FMI,
and lLMI. FMI and VAT analyses were adjusted for age, smoking, group, and lLMI. tLMI and lLMI analyses were adjusted for age, smoking, group, and FMI
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(p = 0.21) and suPAR (p = 0.17) were higher in Non-Lipo
than Controls, though not significantly.
Adjusted analyses for leptin, IL-6, and suPAR and the
association with adipose tissue
When adjusting for age, smoking, group, and lLMI; leptin
and IL-6 were strongly associated with FMI and VAT,
whereas suPAR was only weakly associated (Table 2). The
association between FMI and leptin differed between
groups, and was significantly stronger for Atrophy (103.6 %
per kg/m2, p = 0.02 vs. Non-Lipo) and Controls (72.4 % per
kg/m2, p < 0.001 vs. Non-Lipo) than for Non-Lipo (30.0 %
per kg/m2). Also the association between FMI and IL-6
(33.0 % per kg/m2, p = 0.06 vs. Non-Lipo) and suPAR
(9.1 % per kg/m2, p = 0.06 vs. Non-Lipo) tended to be
stronger for Controls than for Non-Lipo. We found no dif-
ference between the groups for the association between lep-
tin, IL-6, and suPAR with VAT.
Adjusted analyses for leptin, IL-6, and suPAR and the
association with lean mass
When adjusting for age, smoking, group and FMI; IL-6
and suPAR were significantly associated with low tLMI
and lLMI, whereas the positive association between lep-
tin and lean mass was attenuated (Table 2). However, in
Controls leptin was still significantly positively associ-
ated with both tLMI (16.2 % per kg/m2, p = 0.004 vs.
Non-Lipo) and lLMI (59.1 % per kg/m2, p = 0.003 vs.
Non-Lipo).
Exclusion of the influential outlier from the Hyper/
Mix group did not change either the univariate or
multiple adjusted analyses significantly. Furthermore,
adjusting for HOMA-IR did not change the esti-
mates of the multiple adjusted analyses.
Correlation between biomarkers
We assessed the association between biomarkers, ad-
justed for group. Leptin and IL-6 were significantly
correlated (15.5 % per pg/mL IL-6 increase; p = 0.02).
There was no significant correlation for leptin and
suPAR (-12.1 % per ng/mL suPAR increase; p = 0.41).
IL-6 and suPAR levels correlated significantly (64.3 %
per ng/mL suPAR increase; p < 0.001). The correla-
tions between biomarkers did not differ significantly
between groups.
Fig. 4 Association between fat and lean mass index, stratified by group. The figure shows individuals from each group and group-specific regression
lines. Atrophy is presented by red circles and the regression line is thick, solid and red; Hyper/Mix by green and squares, and the regression line is thin,
solid and green; Controls by black and triangles, and the regression line is thick, dotted and black. Non-Lipo by blue and plus, and the regression line
is thin, dotted, and blue. Abbreviation: VAT: visceral adipose tissue
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Discussion
Inflammation has been intensively studied in age-associated
complications. However, it is not clear whether it is the
same inflammatory changes that are central in all age-
associated complications. We therefore studied leptin, IL-6
and suPAR that we hypothesised would be associated dis-
tinctively with lipodystrophy, adiposity and sarcopenia. Lep-
tin levels were significantly elevated in lipodystrophy of the
Hypertrophic or Mixed type (Hyper/Mix) compared to
HIV-infected patients without lipodystrophy (Non-Lipo). In
contrast, IL-6 or suPAR levels were not changed in lipody-
strophy, but tended to be higher in HIV-infected patients
than Controls. Leptin was a strong marker of fat mass. In
contrast, suPAR showed strong associations with low lean
mass, and weak associations with fat mass. IL-6 was a
marker of both increased fat and low lean mass. Thus we
found leptin, IL-6 and suPAR to be associated with lipody-
strophy, adiposity and sarcopenia distinctively.
For the first time we show that leptin levels were signifi-
cantly elevated in patients with Hyper/Mix type lipody-
strophy compared to Non-Lipo, not only as a result of the
fat mass or the insulin sensitivity. In contrast, leptin levels
were not significantly lower in patients with lipoatrophy,
than what was expected from their low fat mass. Results
from other studies suggest that the elevated leptin levels
do not appear to be a general feature of age-associated AT
re-distribution [19]. The elevated leptin levels in Hyper/
Mix type lipodystrophy could be a physiological response
to counteract ectopic fat-mediated lipotoxicity, as leptin
exhibits lipotoxicity-protective effects [20]. However, the
higher leptin levels could also represent a state of leptin
resistance contributing to insulin resistance.
IL-6 and suPAR levels were not altered in lipody-
strophy of either subtype, in agreement with most
studies [18, 27]. In contrast, IL-6 and suPAR levels
were elevated in Non-Lipo compared to Controls,
though not significantly in multiple adjusted ana-
lyses. Along with the highly elevated CD8+ T cell
counts and the lower CD4+/CD8+ T cell ratio, these
findings support that the immune system has not
been fully normalised in HIV-infected patients des-
pite successful treatment, in agreement with previous
studies [8]. The chronic immune activation could be
involved in the earlier onset of comorbidities in
HIV-infected patients.
FMI and tLMI and lLMI were positively associated,
in agreement with the increase in lean mass required
to carry an increased fat mass previously reported
[31]. However, in Hyper/Mix the association appeared
disturbed, also when removing an influential outlier.
Whether this is an artefact, or whether Hyper/Mix
type lipodystrophy is associated with dysregulation of
muscle homeostasis as in sarcopenic obesity, is not
possible to determine in this study.
Leptin and IL-6 were significantly associated with FMI
and VAT in both univariate and multiple regression ana-
lyses. In contrast, suPAR was only significantly associ-
ated with FMI and VAT in multiple regression analyses,
in agreement with previous studies [1, 19]. This did not
appear to be a result of insulin resistance, since adjusting
for HOMA-IR did not change the estimates. When
adjusting for fat mass, IL-6 was independently associated
with low lean mass, in contrast to the univariate analysis.
Moreover, we confirmed our previous finding that
suPAR reflects low lean mass in HIV-infected patients
and extended this to healthy Controls [29]. Neither the
association with suPAR nor IL-6 and low lean mass was
explained by self-reported physical activity (data not
shown). The association of suPAR with low lean mass
may provide new insight into why suPAR is a risk marker
for mortality.
Our findings, of inflammatory biomarkers being asso-
ciated distinctively with age-related processes, are in
agreement with other studies, where it was reported that
inflammatory biomarkers were distinctively associated
with disease severity, and with risk factors leading to dis-
ease development [30, 32]. This indicates that different
inflammatory processes can be active simultaneously
contributing to the systemic low grade inflammatory
state. CCAAT-enhancer-binding proteins (C/EBP) and
specificity protein (SP)-1 are transcription factors for
both the leptin and IL-6 genes. Thus, on the molecular
level, the association between leptin and IL-6 and adi-
posity could be the result of pathways leading to C/EBP
and SP-1 binding to the promoter regions of the leptin
and IL-6 genes [33–35]. However, the different inflam-
matory processes also affect each other, as leptin and IL-
6 affect the production of each other. It is not well
understood, whether suPAR is regulated by, or regulates
other inflammatory mediators [36, 37].
On the cellular level, adiposity-associated inflamma-
tion may result from an increased adipocyte size leading
to AT stress. AT stress could induce adipocyte death, in-
flammation, and macrophage infiltration [38–40]. How-
ever, inflammation can also induce AT stress, thereby
initiating a vicious cycle. More specifically, enlarged adi-
pocytes may contribute significantly to the elevated lep-
tin levels, since leptin is produced in amounts
proportional to fat cell size [41]. AT-derived IL-6 can be
produced by stressed adipocytes or by infiltrating macro-
phages. Elevated IL-6 levels may contribute to disease
development, by increasing the expression of cytokines
like TNF-α known to induce insulin resistance, or by in-
ducing insulin resistance itself [5, 42, 43].
Muscle leptin expression is very small, thus leptin
does not appear to be involved in muscle pathology
[33]. Inflammation could cause muscle atrophy by in-
creasing Nuclear Factor-κB expression that is known to
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activate atrogen gene expression in muscle [26]. IL-6 may
promote muscle catabolism directly through signal trans-
ducer and activator of transcription 3 resulting in Atrogin-1
expression. However, IL-6 anabolic effects have also been
reported [24]. IL-6 catabolic effects may first ensue in a per-
sistent inflammatory state and thus be dependent on other
inflammatory mediators.
The uPAR ligand urokinase plasminogen activator
(uPA) exhibits muscle anabolic properties, independently
of its binding to uPAR [44–47]. suPAR may directly
affect muscle homeostatis by binding uPA. suPAR is
cleaved from the cell surface by proteases involved in
extracellular matrix degradation. The increased suPAR
levels associated with low muscle mass, could therefore
also be a result of the tissue re-modulation taken place
during muscle atrophy [26, 28]. However, underlying
pathophysiological processes could give rise to elevated
suPAR and IL-6 levels, and low muscle mass, without
any direct muscle atrophic effects of suPAR and IL-6.
There are some limitations to our study. The study
was cross-sectional, and we could therefore not examine
the role of leptin, IL-6, and suPAR in the development
of complications. Moreover, our Control and lipodystro-
phy subgroups were small, and our findings should
therefore be confirmed in larger studies. Furthermore, to
understand whether the inflammatory changes identified
here are indeed part of the pathophysiologic process,
studies at the molecular level should be carried out. Our
findings for patients with lipoatrophy are representative
for relatively normo-metabolic patients, since inclusion
criteria were no lipid-lowering or anti-diabetic treat-
ment. Furthermore, our study was designed to assess
lipodystrophy, and not lipodystrophy subtypes, and few
patients with the lipohypertrophic phenotype were in-
cluded. We therefore grouped patients with lipohyper-
trophy and mixed type lipodystrophy. Our findings
support those from other studies, in that lipodystrophy
phenotypes should be analysed separately [21, 48]. Fi-
nally, we could not determine the impact of the HIV in-
fection itself, since no cART naïve HIV-infected group
was included.
Conclusion
Our findings add to the growing knowledge of inflamma-
tion involved in adiposity, adipose tissue redistribution
and sarcopenia. In line with other studies, we showed that
fat mass and lean mass are correlated, which could con-
found the relation between body composition and inflam-
mation if both muscle and fat is not taken into account.
In conclusion, we showed that leptin levels are elevated in
Hyper/Mix type lipodystrophy not only as a result of the
fat mass. This suggests that the leptin system is central in
the pathophysiology of Hyper/Mix type lipodystrophy. In
contrast, suPAR appeared to primarily reflect sarcopenia-
associated inflammation, whereas IL-6 was central in both
adiposity- and sarcopenia-associated inflammation. These
findings suggest that leptin, IL-6 and suPAR are associated
distinctively with various complications of both ageing
and HIV-infection. Identifying major contributors to cir-
culating leptin, IL-6, and suPAR levels could therefore im-
prove our understanding of which processes leads to
distinct age-related complications.
Methods
Microdialysis results from 18 subjects of the study have
been published as part of a microdialysis methodological
study [49].
Ethics
The local ethics committee of the Capital Region of
Denmark (H-4-2010-045), and the Danish Data protec-
tion agency (2010-41-4952) approved the study. We car-
ried out the study according to the declaration of
Helsinki. Written informed consent was obtained from
all participants.
Subjects
We included 60 HIV-infected patients from the Department
of Infectious Diseases, Copenhagen University Hospital,
Hvidovre, Denmark, and 16 healthy men (Controls) from
November 2010 through October 2012. Controls were re-
cruited by advertisement at Hvidovre Hospital. Inclusion
criteria were: male; age older than 18 years; White ethnicity;
no current Hepatitis B (HBV) and/or C (HCV) infection;
no current immunomodulating treatment or disease; no
current lipid-lowering, anti-diabetic or endocrinologic treat-
ment; no intravenous drug use. Moreover, the HIV-
infected patients also had to fulfil: at least 12 month on
cART; CD4+ cell counts ≥200 cells/μL; HIV-RNA <400
copies/mL. Controls were tested negative for HIV, HBV,
and HCV before inclusion, and it was ensured that mean
age was similar in patients and Controls.
Study protocol
Blood samples were collected in the morning after an
overnight fast of eight hours. All subjects completed
a self-administered questionnaire including: tobacco
use; AT distribution; and physical activity. Anthro-
pometry was performed as in Andersen et al. [50],
and included: body weight, height, waist and hip cir-
cumference. Blood pressure was measured after mini-
mum one hour of rest. All participants were told to
refrain from vigorous exercise the day before examination,
physical activity on the examination day, and the use of
any pain killers the week before the examination.
Whole body composition was evaluated by Dual en-
ergy X-ray absorptiometry (DXA) scan (Norland XR-36,
Gammatec A/S, Værløse, Denmark). An experienced
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radiologist evaluated abdominal SAT and VAT mass by
single slice computed tomography (CT) scan (Somatom
Sensation 10, Siemens) at the upper limit of L4 as previ-
ously described in Hansen et al. [51].
Lipodystrophy was determined by physical examin-
ation by a trained examiner. Fat atrophy or hyper-
trophy in the face, retroauricular region, dorsocervical
region, upper arms, thighs, buttocks, and abdominal
subcutaneous and visceral regions was assessed. Pa-
tients were characterised as lipodystrophic (Lipo) if at
least one sign of atrophy and/or hypertrophy was
present, as in Andersen et al. [50]. Patients were not
characterised as lipodystrophic (Non-Lipo) if no other
signs of lipodystrophy than abdominal obesity were
present. Patients were characterised as atrophic (Atrophy)
if only signs of lipoatrophy were present; hypertrophic
(Hyper) if only signs of lipohypertrophy were present, and
Mixed type (Mix) if both lipoatrophy and lipohypertrophy
was present.
Body composition measures
Total and regional lean and fat mass was derived
from DXA scans. Lean mass was used as a surrogate
marker for muscle mass, since lean mass is primarily
constituted of skeletal muscle, especially appendicular
lean mass [52]. Fat and lean mass measures were
constructed as previously described in Kelly et al.
[53]: Fat mass index (FMI) was evaluated as: total fat
mass/height2 (kg/m2). Total lean mass index (tLMI)
as: total lean mass/height2 (kg/m2). Leg lean mass
index (lLMI) as: lean mass of legs/height2 (kg/m2).
Central SAT as: SAT area (cm2). Central VAT as: VAT
area (cm2). Metabolic syndrome was assigned accord-
ing to the 2009 metabolic syndrome consensus defin-
ition [54]. We used ≥94 cm as waist circumference
cut-off as recommended for high risk populations.
Blood sample measurements
CD4+ and CD8+ T-cell numbers, HIV RNA, and glucose
were measured as part of the routine patient management.
Insulin was measured in plasma by the Immulite® 2000
Systems (Siemens®, NY, USA). Plasma suPAR was mea-
sured with the suPARnostic® ELISA (ViroGates A/S,
Birkerød, Denmark) with a mean coefficient of variation
(CV) of 4 %. Plasma IL-6 was measured with Quantikine®
HS-IL-6 ELISA (R&D Systems, Minneapolis, USA) with a
mean CV of 8 %. Plasma leptin was measured with
Quantikine® Leptin ELISA (R&D Systems, Minneapolis,
USA) with a mean CV of 3 %. Insulin resistance was
calculated using the homeostatic model assessment
of insulin resistance (HOMA-IR) as described by
Matthews et al. [55].
Statistics
We assessed the effect of lipodystrophy on biomarker
levels by comparing biomarker levels in lipodystrophy
subgroups and Non-Lipo, and of HIV/cART by compar-
ing biomarker levels in Non-Lipo and Controls. Differ-
ences in baseline characteristics between groups were
analysed by one-way Anova models. If residuals were
not normally distributed, we used Kruskal-Wallis tests.
Group differences in smoking, HIV, previous thymidine
nucleoside reverse transcriptase inhibitor (tNRTI) expos-
ure, RNA >20 copies/mL, and metabolic syndrome were
analysed by χ2 or Fisher’s exact test if less than five indi-
viduals were expected in a group.
The association of biomarkers with fat and lean mass
was analysed by linear regression analyses and tested for
group interactions with biomarker level as outcome. The
association between fat and lean mass was analysed in a
similar manner with lean mass as outcome. The associ-
ation of biomarkers with age, group, smoking, fat and
lean mass, was analysed in univariate analyses and mul-
tiple regression analyses adjusted for biological relevant
covariates with biomarker level as outcome.
We investigated goodness of fit of the linear regression
models for normal distribution of residuals and homogen-
eity of variance. If residuals were not normal, biomarker
levels were transformed using log2(x) to obtain normal
distributed residuals. Results from regression analyses
were therefore back-transformed using 1-2β, and shown as
percent estimates per unit increase. P-values less than 0.05
were considered statistically significant. The statistics pro-
gram”Statistical Analysis Systems” (SAS, version 9.3; SAS
Institute, Cary, NC, USA) was applied for analyses. Graphs
were made using Graph Pad Prism (GraphPad Software
Inc., San Diego, CA, USA) and the statistical software R
(version 2.15.2, R foundation).
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